Investigational Site Number :2500001

Paris 75877

3 studies enrolling now · 19 studies all time

What they study most

Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Acute Myeloid Leukemia, Alport Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasia, Breast Cancer, Celiac Disease, Chronic Graft Versus Host Disease, Chronic Kidney Diseases, Coeliac Disease, Focal Segmental Glomerulosclerosis

Studies at this site

• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) — Recruiting now
• First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) — Stopped early
• A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease — Running, not enrolling
• BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) — Running, not enrolling
• A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia — Running, not enrolling
• Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura — Completed
• A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. — Running, not enrolling
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early
• Study of Lademirsen (SAR339375) in Patients With Alport Syndrome — Stopped early
• Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia — Stopped early
• Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease — Completed
• A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD) — Completed
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk — Stopped early
• A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation — Stopped early
• First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome — Stopped early
• Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA — Stopped early
• Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia — Stopped early